Sung Lee Net Worth

The estimated Net Worth of Sung Lee is at least $2.67 Milion dollars as of 27 March 2024. Mr. Lee owns over 6,008 units of Sangamo Therapeutics Inc stock worth over $84,413 and over the last 5 years he sold SGMO stock worth over $59,419. In addition, he makes $2,530,680 as Chief Financial Officer a Executive Vice President at Sangamo Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lee SGMO stock SEC Form 4 insiders trading

Sung has made over 1 trades of the Sangamo Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 6,008 units of SGMO stock worth $59,419 on 27 March 2024.

The largest trade he's ever made was selling 6,008 units of Sangamo Therapeutics Inc stock on 27 March 2024 worth over $59,419. On average, Sung trades about 858 units every 0 days since 2019. As of 27 March 2024 he still owns at least 100,492 units of Sangamo Therapeutics Inc stock.

You can see the complete history of Mr. Lee stock trades at the bottom of the page.

Sung Lee biography

Sung H. Lee serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Lee served in various roles at Gilead Sciences, Inc. since 2005 before joining the Company, most recently as Senior Vice President, Financial Planning & Analysis, or FP&A, and Investor Relations from March 2019 to October 2019. Previously, Mr. Lee served as Vice President of FP&A and Investor Relations from September 2018 to February 2019, Vice President of Investor Relations from June 2016 to August 2018, and Senior Director, Investor Relations from 2013 to May 2016. From 2010 to 2013, Mr. Lee was the Head of Europe FP&A at Gilead and prior to that served as the Head of Research & Development FP&A from 2006-2010. Mr. Lee received a B.A. from University of California, Irvine and an M.B.T. from University of Southern California.

What is the salary of Sung Lee?

As the Chief Financial Officer a Executive Vice President of Sangamo Therapeutics Inc, the total compensation of Sung Lee at Sangamo Therapeutics Inc is $2,530,680. There are 1 executives at Sangamo Therapeutics Inc getting paid more, with Alexander Macrae having the highest compensation of $3,986,560.

How old is Sung Lee?

Sung Lee is 49, he's been the Chief Financial Officer a Executive Vice President of Sangamo Therapeutics Inc since 2019. There are 14 older and 4 younger executives at Sangamo Therapeutics Inc. The oldest executive at Sangamo Therapeutics Inc is H. Stewart Parker, 64, who is the Independent Director.

What's Sung Lee's mailing address?

Sung's mailing address filed with the SEC is 350 OYSTER POINT BLVD, , SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Sangamo Therapeutics Inc

Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp a Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.

What does Sangamo Therapeutics Inc do?

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.

Complete history of Mr. Lee stock trades at Cytokinetics Inc, Sangamo Therapeutics Inc a Vir Biotechnology Inc

Sangamo Therapeutics Inc executives and stock owners

Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include:

• Alexander Macrae,
  President, Chief Executive Officer, Director
• Sung Lee,
  Chief Financial Officer, Executive Vice President
• Gary Loeb,
  Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
• Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.,
  CEO, Pres & Director
• R. Andrew Ramelmeier,
  Executive Vice President - Technical Operations
• Dr. R. Andrew Ramelmeier Ph.D.,
  Exec. VP of Technical Operations
• D. Mark McClung,
  Exec. VP & COO
• James Meyers,
  Independent Director
• H. Stewart Parker,
  Independent Director
• Joseph Zakrzewski,
  Independent Director
• Robert Carey,
  Independent Director
• Saira Ramasastry,
  Independent Director
• Karen Smith,
  Independent Director
• McDavid Stilwell,
  IR Contact Officer
• John Markels,
  Independent Director
• Kenneth Hillan,
  Director
• Prathyusha Duraibabu,
  Vice President - Finance
• D. Mark McClung,
  Executive Vice President, Chief Business Officer
• Scott B. Willoughby,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Prathyusha Duraibabu CPA, M.B.A.,
  Sr. VP, CFO & Principal Accounting Officer
• Dr. Jason D. Fontenot Ph.D.,
  Sr. VP & Chief Scientific Officer
• Prathyusha Duraibabu,
  VP of Fin., Principal Accounting Officer & Principal Financial Officer
• Dr. Duncan McKay,
  Sr. VP & GM of Europe
• Heather Erickson,
  Chief of Staff
• Dr. Nathalie Dubois-Stringfellow,
  Sr. VP of Product Devel. & Management
• Whitney Jones,
  Sr. VP & Chief People Officer
• Aron Feingold,
  Head of Corp. Communications & Investor Relations Officer
• Dr. Jason Fontenot Ph.D.,
  Sr. VP & Chief Scientific Officer
• Stephen George Dilly,
  Director
• Paul B Cleveland,
  Director
• Henry Ward Wolff,
  Director
• Steven J Mento,
  Director
• William R Ringo,
  Director
• Geoffrey Nichol,
  Executive Vice President, R&D
• Curt A. Iii Herberts,
  Sr.VP & Chief Business Officer
• Dale G Ando,
  VP, Therapeutic Dev. & CMO
• Edward R. Conner,
  Sr. VP & Chief Medical Officer
• Thomas G Wiggans,
  Director
• William G Gerber,
  Director
• Roger Jeffs,
  Director
• Heather D Turner,
  EVP, General Counsel & Sec.
• Robert J. Schott,
  SVP, Head of Development
• Stephane Boissel,
  EVP, Corp. Strategy
• Kathy Yi,
  EVP & Chief Financial Officer
• Margaret Liu,
  Director
• Michael C Wood,
  Director
• Greg Zante,
  Sr Dir., Finance and Admin
• Le Roy C Kopp,
  10% owner
• Edward O Ii Lanphier,
  President and CEO
• Jon E M Jacoby,
  Director
• Casey C Case,
  Vice President, Research
• Peter Bluford,
  V.P., Corporate Development
• William J Rutter,
  Director
• John William Larson,
  Director
• Philip D Gregory,
  Vice President, Research
• Capital Management, L.P.Ra ...,
  
• David G Ichikawa,
  Senior VP, Bus. Dev.
• Jason D. Fontenot,
  SVP, Chief Scientific Officer
• Scott B. Willoughby,
  SVP, GEN. COUNSEL & SECRETARY
• Inc.Biogen Ma Inc. Biogen,
  
• Sandy Macrae,
  PRESIDENT, CEO AND DIRECTOR
• Nathalie Dubois Stringfellow,
  SVP-CHIEF DEVELOPMENT OFFICER
• Amy Pooler,
  VP, HEAD OF RESEARCH
• Courtney Beers,
  
• Margaret A Horn,